NEW YORK, Nov 27 – Qiagen and Luminex have agreed to jointly develop consumable kits and assays using Luminex’s Labmap technology, the companies announced Monday.
Under the agreement, Qiagen will market the assay detection products beginning in the third quarter of 2001. Luminex has received an upfront payment for the Labmap technology, and will receive future royalty payments from Qiagen based on the sale of kits and reagents.
" We believe that our customers in drug development and genomics will find this integration of our and Luminex's technologies to significantly increase the throughput, cost and flexibility of the analytical procedures these products will address,” said Qiagen CEO Metin Colpan in a statement.
The Labmap technology uses microspheres, small lasers, digital processors, and software to perform up to 100 assays per drop of fluid. As their first joint product, the two companies are planning to utilize this technology to develop fluorescent microspheres coated with Qiagen’s proprietary affinity ligands. These microspheres will allow researchers to immobilize functionally active proteins. The total kit is designed to enable a range of assays and analysis of proteins, histidin-tagged drug targets, or antigens on a single platform, Qiagen said.
The companies also plan to develop an integrated lab assay system that combines Qiagen’s line of bio-robotic liquid handling instrumentation with Luminex’s detection and analysis technology. The companies expect this system to be available toward the end of next year.
Luminex has licensed the Labmap technology to over 18 other companies as part of its strategy to commercialize the technology through partnerships with other companies.